3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
7
Tumor-Agnostic
2
Conditions
Neoplasms
4
Carcinoma
2
Neoplasm Metastasis
1
Interventions
Paclitaxel
9
Carboplatin
9
pembrolizumab
7
Radiotherapy
7
Cisplatin
5
Axitinib
4
Pemetrexed
3
Nivolumab
3
trifluridine tipiracil drug combination
2
regorafenib
2
osimertinib
2
fludarabine
2
dacomitinib
2
catumaxomab
2
Trastuzumab
2
Sunitinib
2
Radiotherapy, Intensity-Modulated
2
Nurses
2
Interleukin-2
2
Gemcitabine
2
Docetaxel
2
Cyclophosphamide
2
Cetuximab
2
Bevacizumab
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
vatalanib
1
temsirolimus
1
sovateltide
1
selinexor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Carcinoma
×
osimertinib
×
Tumor-Agnostic
×
Clear all
NCT05261399
2026-04-06
SAFFRON
AstraZeneca
Phase 3
Active not recruiting
345 enrolled
NCT02529995
2020-02-11
AURAChinaPK
AstraZeneca
Phase 1
Completed
31 enrolled
22 charts